IMRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Immuneering's sale of business for the three months ended in Sep. 2024 was $0.00 Mil. It means Immuneering gained $0.00 Mil from selling business. Immuneering's sale of business for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.
Compared with last quarter ($0.00 Mil in Jun. 2024 ), Immuneering gained the same money from selling business in Sep. 2024 ($0.00 Mil).
The historical data trend for Immuneering's Sale Of Business can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuneering Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Sale Of Business | - | - | 0.07 | - | - |
Immuneering Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Sale Of Business | Get a 7-Day Free Trial | - | - | - | - | - |
The amount earned to sell business.
Sale Of Business for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Immuneering's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Harold Eugene Brakewood | officer: Chief Business Officer | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
Mallory Morales | officer: Vice President, Finance | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
Peter Feinberg | director | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
Leah R Neufeld | officer: Chief People Officer | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
Brett Matthew Hall | officer: Chief Scientific Officer | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
Benjamin J. Zeskind | director, 10 percent owner, officer: President and CEO | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
Ann E Berman | director | 255 STATE STREET, BOSTON MA 02109 |
Bihua Chen | 10 percent owner | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Master Fund, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Iii Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Michael Bookman | officer: General Counsel and Secretary | C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801 |
Laurie Keating | director | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Biren Amin | officer: CFO, Treasurer | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
Scott Barrett | officer: Chief Medical Officer | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
From GuruFocus
By sperokesalga sperokesalga • 02-27-2023
By Ds*** Ds*** • 09-02-2022
By sperokesalga sperokesalga • 04-18-2023
By sperokesalga sperokesalga • 05-30-2023
By Value_Insider Value_Insider • 11-03-2022
By Marketwired • 11-13-2024
By sperokesalga sperokesalga • 04-12-2023
By Marketwired • 10-12-2023
By Marketwired • 08-06-2024
By sperokesalga sperokesalga • 06-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.